According to a press release from the company, an interim analysis of clinical trials of this vaccine showed its average effectiveness at 70%.
It is specified that this indicator is based on data on the effectiveness of two dosing regimens.
In the first case, the vaccine was administered as a half dose, followed by a full dose at an interval of at least one month, and in the second, two full doses were administered at an interval of at least one month.
The first mode showed efficiency at 90%, and the second at 62%.
As a result, the combined analysis of both modes resulted in an average efficiency of 70%.
Earlier, US President Donald Trump said that the final analysis of data from clinical trials of the coronavirus vaccine developed by Pfizer and BioNTech showed its effectiveness at the level of 95%.